SUN-297 LEVOFLOXACIN BASED NON-RIFAMPICIN ANTI-TUBERCULOUS THERAPY- AN EFFECTIVE ALTERNATIVE IN RENAL TRANSPLANT RECIPIENTS IN RESOURCE LIMITED SETTING

Rifampicin is one of the most effective anti-tuberculous therapy. Rifampicin is an enzyme inducer and hence, in a post-renal transplant recipient, the dose of calcineurin inhibitors needs to be frequently monitored and modulated accordingly. In resource-limited (low- and middle-income countries) setting this is not always feasible. So, we evaluated a non-rifampicin based anti-tuberculosis therapy (ATT) using levofloxacin in kidney transplant recipients.